Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys

The combination of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonists resulted in a 6.6% reduction in body weight in diet-induced obese, diabetic nonhuman primates.

• The selective GLP-1R agonist alone decreased energy intake by 18% and body weight by 3.8%.
• Subcutaneous administration of the GCGR agonist did not impact food intake or body weight.
• The combination therapy significantly reduced cumulative food intake by 27%.
• Fasting plasma glucose improved from 176.7 mg/dL to 115.9 mg/dL with GLP-1R agonist treatment.
• Chronic GCGR agonist administration was associated with nonsignificant increases in fasting plasma glucose.
• In the combination group, there was a nonsignificant increase in glucose excursion alongside significantly increased insulin secretion.

AI simplified